feed,title,long_url,short_url
Benzinga,FDA Reissues Emergency Use Authorization For LumiraDx's COVID-19 Testing Solution,https://benzinga.com/news/21/12/24384832/fda-reissues-emergency-use-authorization-for-lumiradxs-covid-19-testing-solution,https://j.mp/3Id8BtF
Benzinga,FDA Pushes Review Of BioXcel's Candidate For Agitation Associated With Neuropsychiatric Disorders,https://benzinga.com/general/biotech/21/12/24380538/fda-pushes-review-of-bioxcels-candidate-for-agitation-associated-with-neuropsychiatric-disorders,https://j.mp/32PNUDQ
Benzinga,Oragenics COVID-19 Vaccine Candidate Shows Encouraging Preclinical Action,https://benzinga.com/general/biotech/21/12/24384314/oragenics-covid-19-vaccine-candidate-shows-encouraging-preclinical-action,https://j.mp/3IbaAOP
Benzinga,BeyondSpring Shares Crater After FDA Rejects Plinabulin Application,https://benzinga.com/general/biotech/21/12/24381737/beyondspring-shares-crater-after-fda-rejects-plinabulin-application,https://j.mp/3xIFn0D
Benzinga,SAB Biotherapeutics' Influenza Candidate Achieves Primary Goal In Mid-Stage Study,https://benzinga.com/general/biotech/21/12/24380808/sab-biotherapeutics-influenza-candidate-achieves-primary-goal-in-mid-stage-study,https://j.mp/3lqP8vI
